Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, Dahlström U, Linde C, Braunschweig F, Savarese G. Schrage B, et al. Among authors: savarese g. Circulation. 2019 Nov 5;140(19):1530-1539. doi: 10.1161/CIRCULATIONAHA.119.043012. Epub 2019 Sep 3. Circulation. 2019. PMID: 31476893
Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry.
Stolfo D, Uijl A, Benson L, Schrage B, Fudim M, Asselbergs FW, Koudstaal S, Sinagra G, Dahlström U, Rosano G, Savarese G. Stolfo D, et al. Among authors: savarese g. Eur J Heart Fail. 2020 Jan;22(1):103-112. doi: 10.1002/ejhf.1615. Epub 2019 Oct 23. Eur J Heart Fail. 2020. PMID: 31478583 Free article.
Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry".
Schrage B, Linde C, Braunschweig F, Savarese G. Schrage B, et al. Among authors: savarese g. Circulation. 2020 Mar 17;141(11):e648-e649. doi: 10.1161/CIRCULATIONAHA.120.045603. Epub 2020 Mar 16. Circulation. 2020. PMID: 32176544 No abstract available.
Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design.
Savarese G, Settergren C, Schrage B, Thorvaldsen T, Löfman I, Sartipy U, Mellbin L, Meyers A, Farsani SF, Brueckmann M, Brodovicz KG, Vedin O, Asselbergs FW, Dahlström U, Cosentino F, Lund LH. Savarese G, et al. Int J Cardiol. 2020 Aug 15;313:76-82. doi: 10.1016/j.ijcard.2020.04.068. Epub 2020 Apr 30. Int J Cardiol. 2020. PMID: 32360702 Free article.
Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM, Schrage B, Ferrannini G, Benson L, Butler J, Carrero JJ, Cosentino F, Dahlström U, Mellbin L, Rosano GMC, Sinagra G, Stolfo D, Lund LH, Savarese G. Becher PM, et al. Among authors: savarese g. Eur J Heart Fail. 2021 Jun;23(6):1012-1022. doi: 10.1002/ejhf.2131. Epub 2021 Mar 2. Eur J Heart Fail. 2021. PMID: 33599357 Free article.
391 results